Pramlintide: Uses, Mechanism, Evidence, and Side Effects

For people with diabetes who still struggle with blood sugar control despite careful mealtime insulin use, treatment options beyond insulin itself are limited. Pramlintide is one such option, an injectable medicine designed to work alongside insulin rather than replace it.

Key takeaways

• Pramlintide is an amylin analog approved as an add-on to mealtime insulin in type 1 or type 2 diabetes.
• It is marketed under the brand name SymlinPen.
• The label carries a boxed warning.
• More than 60 registered trials have studied pramlintide, including completed Phase 4 and Phase 2 work.
• FAERS reports most often mention blood glucose changes and kidney-related events, which reflect reporting patterns rather than confirmed causes.

What Pramlintide Is

Pramlintide is a synthetic analog of human amylin, a hormone normally released by the pancreas alongside insulin after eating. In healthy people, amylin and insulin are secreted together in response to food. People with diabetes often secrete less of both hormones, and pramlintide is designed to replace the missing amylin signal.

What Pramlintide Is Approved For

Pramlintide, sold as SymlinPen, is approved as an adjunctive treatment for adults with type 1 or type 2 diabetes who use mealtime insulin but have not reached their glucose goals despite optimal insulin therapy. It is intended for use in addition to insulin, not as a substitute for it. The label includes a boxed warning, which prescribers and patients should be aware of.

What the Evidence Shows

Pramlintide has been studied in 66 registered clinical trials. A completed Phase 4 trial examined combining exenatide and pramlintide to reduce after-meal blood sugar spikes. An earlier Phase 2 trial evaluated the bioavailability of pramlintide, while a Phase 3 trial on high-dose Symlin for type 2 diabetes has an unknown completion status.

Reported Side Effects

Reports submitted to the FDA Adverse Event Reporting System (FAERS) most frequently describe changes in blood glucose, with increased blood glucose being the single most reported term. Kidney-related events, including acute kidney injury, chronic kidney disease, and renal failure, also appear repeatedly in these reports. Other commonly reported terms include nausea, fatigue, dyspnoea, and hypertension. These figures represent counts of submitted reports, not confirmed rates of occurrence or evidence that pramlintide caused the event.